---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-005311"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:49:42.902667+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CNS Pharmaceuticals regains Nasdaq equity compliance after $9.9M share sale

## Summary
- Shareholders' equity exceeds $5.0M, above Nasdaq's $2.5M minimum for continued listing.
- Sold 23,091,315 shares under A.G.P. agreement for gross proceeds of ~$9.9M.
- Cash on deposit $9.6M; company expects to fund operations through Q1 2025.
- Nasdaq Panel had granted final extension to Aug 12, 2024; delisting risk now resolved.

## SEC filing metadata
- accession: 0001683168-24-005311
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824005311/0001683168-24-005311-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824005311/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-005311
- JSON: https://secwatch.observer/filing/0001683168-24-005311.json
- Plain text: https://secwatch.observer/filing/0001683168-24-005311.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.